Highlights

  • IYH seeks exposure to US healthcare equities spanning pharmaceuticals, biotechnology and medical equipment.
  • The fund reports NAV of USD 77.56 as of 2 November 2026.
  • IYH lists an expense ratio of 0.37% and distributes quarterly.

iShares U.S. Healthcare ETF (NYSE Arca:IYH) seeks to track US healthcare equities spanning pharmaceuticals, biotechnology and medical equipment. Its NAV stood at USD 77.56 as of 2 November 2026. Net Assets totalled USD 4,692,272,313 as of 2 November 2026.

Several Healthcare Activities Within One Benchmark

IYH tracks the Russell 1000 Health Care RIC 22.5/45 Capped Index. The benchmark draws healthcare companies from a large- and mid-cap US Equity universe and applies issuer-weight constraints. The mandate combines several healthcare activities within a single sector index. Its composition follows the index’s industry classifications and constituent rules.

The fund uses representative sampling, selecting investments intended to resemble the benchmark’s overall characteristics. It may therefore hold a different collection of securities from the index while seeking a similar Investment profile.

Portfolio Composition and Exposure

IYH reported 100 holdings as of 30 October 2026. Its allocation by Market Value included Pharmaceuticals at 37.51%, Biotechnology at 24.05% and Health Care Equipment at 13.94% as of 30 October 2026.

The fact sheet dated 30 September 2026 identified holdings including Eli Lilly at 14.55%, Johnson & Johnson at 10.05% and AbbVie at 7.30%. These position weights refer to that reporting date and can change as the portfolio and market values evolve.

The same fact sheet reported a P/E ratio of 29.66x and a P/B ratio of 5.14x. These valuation measures complement the holdings information with Earnings and book-value characteristics associated with the equity portfolio.

Fees and Distribution Policy

The published expense ratio is 0.37%. Distributions are scheduled quarterly.

The 30-day SEC Yield was 1.10% as of 30 September 2026. This standardised income measure reflects the fund’s recent income after expenses; it is separate from changes in the market value of its shares.

The prospectus notes that brokerage commissions and other intermediary charges may apply separately. Fund shares trade at market prices, which can differ from NAV, so the stated NAV does not establish the price of every exchange transaction.

Key Insights

Regulation, product approvals, reimbursement arrangements and competition can affect healthcare businesses. The portfolio remains exposed to both developments shared across the sector and changes affecting individual issuers.